Primary Care Rx Market Offers Second-Rate Return On Investment – Bristol
Executive Summary
Pharmaceutical companies marketing primary care products are unlikely to see a significant return on their investment, Bristol-Myers Squibb CFO Andrew Bonfield declared June 10
You may also be interested in...
Roche Pipeline Potency Validates No-Merger Stance, Company Says
Roche has the third largest pipeline of new molecular entities in development in the drug industry, the company maintained during an R&D day in New York City May 6
Merck Gets Second Chance On Dual PPAR: Will Develop Bristol’s Muraglitazar
Merck's co-development agreement for Bristol Myers-Squibb's Phase III muraglitazar gives the company a second chance to market a dual PPAR agonist
Bristol Rethinking Sales Model, May Try New Approach To Sampling
Bristol-Myers Squibb is reexamining the role of sales forces to find new ideas for reaching physicians